JP7181857B2 - Ｃｘｃｒ３受容体アゴニスト - Google Patents
Ｃｘｃｒ３受容体アゴニスト Download PDFInfo
- Publication number
- JP7181857B2 JP7181857B2 JP2019512307A JP2019512307A JP7181857B2 JP 7181857 B2 JP7181857 B2 JP 7181857B2 JP 2019512307 A JP2019512307 A JP 2019512307A JP 2019512307 A JP2019512307 A JP 2019512307A JP 7181857 B2 JP7181857 B2 JP 7181857B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- compound
- dcm
- groups
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383202P | 2016-09-02 | 2016-09-02 | |
| US62/383,202 | 2016-09-02 | ||
| US201762478496P | 2017-03-29 | 2017-03-29 | |
| US62/478,496 | 2017-03-29 | ||
| PCT/US2017/049768 WO2018045246A1 (en) | 2016-09-02 | 2017-08-31 | Cxcr3 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533639A JP2019533639A (ja) | 2019-11-21 |
| JP2019533639A5 JP2019533639A5 (enExample) | 2020-10-01 |
| JP7181857B2 true JP7181857B2 (ja) | 2022-12-01 |
Family
ID=59846729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512307A Active JP7181857B2 (ja) | 2016-09-02 | 2017-08-31 | Ｃｘｃｒ３受容体アゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190345133A1 (enExample) |
| EP (1) | EP3507275B1 (enExample) |
| JP (1) | JP7181857B2 (enExample) |
| AU (1) | AU2017318674B2 (enExample) |
| CA (1) | CA3034108A1 (enExample) |
| ES (1) | ES2950560T3 (enExample) |
| MX (1) | MX380217B (enExample) |
| WO (1) | WO2018045246A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4103223A4 (en) | 2020-02-12 | 2024-05-29 | The Regents of the University of California | PLATELET FACTORS AND COGNITIVE IMPROVEMENT |
| CN111943823A (zh) * | 2020-09-16 | 2020-11-17 | 安徽工业大学 | 一种苯菌酮的制备方法 |
| CN116178383B (zh) * | 2022-12-26 | 2025-04-22 | 南方科技大学 | 生物碱及三价铁卟啉催化合成生物碱的方法 |
-
2017
- 2017-08-31 ES ES17765033T patent/ES2950560T3/es active Active
- 2017-08-31 JP JP2019512307A patent/JP7181857B2/ja active Active
- 2017-08-31 MX MX2019002166A patent/MX380217B/es unknown
- 2017-08-31 WO PCT/US2017/049768 patent/WO2018045246A1/en not_active Ceased
- 2017-08-31 AU AU2017318674A patent/AU2017318674B2/en not_active Ceased
- 2017-08-31 US US16/335,641 patent/US20190345133A1/en not_active Abandoned
- 2017-08-31 CA CA3034108A patent/CA3034108A1/en not_active Abandoned
- 2017-08-31 EP EP17765033.0A patent/EP3507275B1/en active Active
-
2020
- 2020-05-11 US US16/872,161 patent/US11040954B1/en active Active
Non-Patent Citations (3)
| Title |
|---|
| Biochemical and Biophysical Research Communications，2006年，Vol.349，pp.221-228 |
| British Journal of Pharmacology，2012年，Vol.166，pp.898-911 |
| Journal of Medicinal Chemistry，2012年，Vol.55，pp.10572-10583 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190345133A1 (en) | 2019-11-14 |
| MX2019002166A (es) | 2019-06-12 |
| JP2019533639A (ja) | 2019-11-21 |
| WO2018045246A1 (en) | 2018-03-08 |
| CA3034108A1 (en) | 2018-03-08 |
| ES2950560T3 (es) | 2023-10-11 |
| US11040954B1 (en) | 2021-06-22 |
| MX380217B (es) | 2025-03-12 |
| AU2017318674A1 (en) | 2019-03-28 |
| EP3507275B1 (en) | 2023-04-26 |
| AU2017318674B2 (en) | 2020-11-12 |
| EP3507275A1 (en) | 2019-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018272359B2 (en) | Lactam compound as FXR receptor agonist | |
| ES2864349T3 (es) | Nuevos moduladores del receptor GLP-1 | |
| EP3704118B1 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| JP2007516298A (ja) | 新規なスピロインドリンまたはスピロイソキノリン化合物、それらの使用方法および組成物 | |
| WO2018089355A1 (en) | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors | |
| WO2012009258A2 (en) | Peptidomimetic galanin receptor modulators | |
| EP2234487A1 (en) | Anilides and analogs as rho kinase inhibitors | |
| CA2859965A1 (en) | Non-systemic tgr5 agonists | |
| AU2016242973A1 (en) | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer | |
| MX2014006622A (es) | Derivados de acido carboxilico que comprenden cuatro ciclos, que actuan como moduladores del receptor del peptido 1 similar al glucagon (glp-1) para terapia de enfermedades como la diabetes. | |
| CA2880494A1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| WO2009079009A1 (en) | Anilides and analogs as rho kinase inhibitors | |
| JP7181857B2 (ja) | Ｃｘｃｒ３受容体アゴニスト | |
| AU2019247842B2 (en) | Opioid receptor modulators and products and methods related thereto | |
| WO2014153529A1 (en) | Substituted benzimidazoles as nociceptin receptor modulators | |
| CA2926754C (en) | Piperazine derivatives and the use thereof as medicament | |
| EP3140294A1 (en) | Pyrrolidine gpr40 modulators | |
| TWI537251B (zh) | Ｆｐｒ１拮抗劑的衍生物及其用途 | |
| KR102514476B1 (ko) | 미엘로퍼옥시다제의 마크로시클릭 억제제 | |
| EP4423094B1 (en) | Rxfp1 modulators for the treatment of heart failure | |
| JP2009523747A (ja) | α７ニコチン性アセチルコリン受容体のモジュレーターおよびその治療上の使用 | |
| KR102819622B1 (ko) | Nop 억제제로서의 치환된 사이클로헥실 화합물 | |
| AU2022228430A1 (en) | Diazepine derivatives useful in the treatment of clostridium difficile | |
| CN106061953A (zh) | 结合至pparg但不用作启动子的化合物和用于治疗与pparg相关的疾病的包含所述化合物作为活性成分的药物学组合物 | |
| RU2776052C2 (ru) | Лактамное соединение в качестве агониста рецептора FXR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20200214 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20200226 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200819 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200819 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210907 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211203 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220131 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220419 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220906 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221115 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221118 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7181857 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |